# Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors

> **NCT03851614** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 90 (estimated)

## Conditions studied

- Mismatch Repair Proficient Colorectal Cancer
- Pancreatic Adenocarcinoma
- Leiomyosarcoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Olaparib
- **DRUG:** Cediranib

## Key facts

- **NCT ID:** NCT03851614
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-08
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03851614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03851614, "Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT03851614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*